Running the numbers

Log In | Sign Up



argenx

Selected Articles

2025-08-11
GlobeNewswire
Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035
2025-08-08
Biztoc.com
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
2025-08-08
GlobeNewswire
Thyroid Eye Disease Pipeline Market Research 2025 | Emerging Therapies Pipeline Features Advanced Monoclonal Antibodies and Novel Inhibitors in Late-Stage Clinical Development
2025-08-08
ETF Daily News
LPL Financial LLC Has $12.36 Million Position in argenex SE (NASDAQ:ARGX)
2025-08-08
ETF Daily News
Analysts Set argenex SE (NASDAQ:ARGX) PT at $746.81
2025-08-07
Yahoo Entertainment
Should You be Confident in Atlassian's (TEAM) Long-Term Growth Drivers?
2025-08-07
Biztoc.com
Here's What Pulled Down Argenx (ARGX) in Q2
2025-08-07
Yahoo Entertainment
Here's What Pulled Down Argenx (ARGX) in Q2
2025-08-07
Yahoo Entertainment
Baker Hughes (BKR) Slid Due to Macro Economic Uncertainty
2025-08-07
ETF Daily News
US Bancorp DE Sells 45 Shares of argenex SE (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. NL0010832176 www.argenx.com